Global Non-alcoholic Fatty Liver Disease Therapeutics Market 2018-2022

非アルコール性脂肪肝疾患治療薬の世界市場2018-2022

◆タイトル:Global Non-alcoholic Fatty Liver Disease Therapeutics Market 2018-2022
◆商品コード:IRTNTR23695
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2018年10月29日
◆ページ数:111
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
◆産業分野:医療・バイオ
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥385,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD5,000 ⇒換算¥550,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、非アルコール性脂肪肝疾患治療薬の世界市場について調査・分析し、市場概要、市場環境、非アルコール性脂肪肝疾患治療薬市場規模、ROA別(経口ROA、非経口ROA)分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。主な分析対象企業は、ALLERGAN, GlaxoSmithKline, Merck, Novartis, Pfizerなどです。
・エグゼクティブサマリー
・調査範囲・調査手法
・非アルコール性脂肪肝疾患治療薬の世界市場概要
・非アルコール性脂肪肝疾患治療薬の世界市場環境
・非アルコール性脂肪肝疾患治療薬の世界市場動向
・非アルコール性脂肪肝疾患治療薬の世界市場規模
・非アルコール性脂肪肝疾患治療薬の世界市場:業界構造分析
・非アルコール性脂肪肝疾患治療薬の世界市場:ROA別(経口ROA、非経口ROA)
・非アルコール性脂肪肝疾患治療薬の世界市場:地域別市場規模・分析
・非アルコール性脂肪肝疾患治療薬の北米市場規模・予測
・非アルコール性脂肪肝疾患治療薬のヨーロッパ・中東・アフリカ市場規模・予測
・非アルコール性脂肪肝疾患治療薬のアジア太平洋市場規模・予測
・非アルコール性脂肪肝疾患治療薬の主要国分析
・非アルコール性脂肪肝疾患治療薬の世界市場:意思決定フレームワーク
・非アルコール性脂肪肝疾患治療薬の世界市場:成長要因、課題
・非アルコール性脂肪肝疾患治療薬の世界市場:競争環境
・非アルコール性脂肪肝疾患治療薬の世界市場:関連企業情報(ベンダー分析)

About Non-alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease is a condition in which excess fat is stored in the liver. There are two types of NAFLD, namely simple fatty liver and non-alcoholic steatohepatitis. In simple fatty liver, the fat in the liver is very less and there is no inflammation or liver cell damage.
Technavio’s analysts forecast the Global Non-alcoholic Fatty Liver Disease Therapeutics Market to grow at a CAGR of 16.19% during the period 2018-2022.

Covered in this report
The report covers the present scenario and the growth prospects of the non-alcoholic fatty liver disease therapeutics market. To calculate the market size, the report considers the revenue generated by the applications of non-alcoholic fatty liver disease therapeutics across the globe.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, non-alcoholic fatty liver disease therapeutics market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
• ALLERGAN
• GlaxoSmithKline
• Merck
• Novartis
• Pfizer
Market driver
• Increasing prevalence of non-alcoholic fatty liver disease
• For a full, detailed list, view our report

Market challenge
• Unclear pathogenesis of non-alcoholic fatty liver disease
• For a full, detailed list, view our report

Market trend
• Growing number of strategic alliances
• For a full, detailed list, view our report

Key questions answered in this report
• What will the market size be in 2022 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【資料の目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 05: MARKET SIZING
• Market definition
• Market sizing 2017
• Market size and forecast
PART 06: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 07: PIPELINE LANDSCAPE
PART 08: MARKET SEGMENTATION BY ROA
• Segmentation by RoA
• Comparison by RoA
• Oral RoA – Market size and forecast 2017-2022
• Parenteral RoA – Market size and forecast 2017-2022
• Market opportunity by RoA
PART 09: CUSTOMER LANDSCAPE
PART 10: REGIONAL LANDSCAPE
• Geographical segmentation
• Regional comparison
• NAFLD therapeutics market in the Americas – Market size and forecast 2017-2022
• NAFLD therapeutics market in EMEA – Market size and forecast 2017-2022
• NAFLD therapeutics market in APAC – Market size and forecast 2017-2022
• Market opportunity
PART 11: DECISION FRAMEWORK
PART 12: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 13: MARKET TRENDS
PART 14: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 15: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• ALLERGAN
• GlaxoSmithKline
• Merck
• Novartis
• Pfizer
PART 16: APPENDIX
• List of abbreviations



Exhibit 01: Parent market
Exhibit 02: Global metabolic disorders therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition: Inclusions and exclusions checklist
Exhibit 06: Market size 2017
Exhibit 07: Validation techniques employed for market sizing 2017
Exhibit 08: Global NAFLD therapeutics market – Market size and forecast 2017-2022 ($ mn)
Exhibit 09: Global NAFLD therapeutics market – Year-over-year growth 2018-2022 (%)
Exhibit 10: Five forces analysis 2017
Exhibit 11: Five forces analysis 2022
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition: Five forces 2017
Exhibit 18: Pipeline landscape by development phase 2017-2018
Exhibit 19: Late-stage pipeline molecules for the treatment of NAFLD 2017-2018
Exhibit 20: Global NAFLD therapeutics market – Market share by RoA 2017-2022 (%)
Exhibit 21: Comparison by RoA
Exhibit 22: Global NAFLD therapeutics market by oral RoA – Market size and forecast 2017-2022 ($ mn)
Exhibit 23: Global NAFLD therapeutics market by oral RoA – Year-over-year growth 2018-2022 (%)
Exhibit 24: Global NAFLD therapeutics market by parenteral RoA – Market size and forecast 2017-2022 ($ mn)
Exhibit 25: Global NAFLD therapeutics market by parenteral RoA – Year-over-year growth 2018-2022 (%)
Exhibit 26: Market opportunity by RoA
Exhibit 27: Customer landscape
Exhibit 28: Global NAFLD therapeutics market by geography – Market share 2017-2022 (%)
Exhibit 29: Regional comparison
Exhibit 30: NAFLD therapeutics market in Americas – Market size and forecast 2017-2022 ($ mn)
Exhibit 31: NAFLD therapeutics market in Americas – Year-over-year growth 2018-2022 (%)
Exhibit 32: Top 3 countries in Americas
Exhibit 33: NAFLD therapeutics market in EMEA – Market size and forecast 2017-2022 ($ mn)
Exhibit 34: NAFLD therapeutics market in EMEA – Year-over-year growth 2018-2022 (%)
Exhibit 35: Top 3 countries in EMEA
Exhibit 36: NAFLD therapeutics market in APAC – Market size and forecast 2017-2022 ($ mn)
Exhibit 37: NAFLD therapeutics market in APAC – Year-over-year growth 2018-2022 (%)
Exhibit 38: Top 3 countries in APAC
Exhibit 39: Market opportunity
Exhibit 40: Vendor landscape
Exhibit 41: Landscape disruption
Exhibit 42: Vendors covered
Exhibit 43: Vendor classification
Exhibit 44: Market positioning of vendors
Exhibit 45: ALLERGAN: Overview
Exhibit 46: ALLERGAN – Business segments
Exhibit 47: ALLERGAN – Organizational developments
Exhibit 48: ALLERGAN – Geographic focus
Exhibit 49: ALLERGAN – Segment focus
Exhibit 50: ALLERGAN – Key offerings
Exhibit 51: ALLERGAN – Key customers
Exhibit 52: GlaxoSmithKline: Overview
Exhibit 53: GlaxoSmithKline – Business segments
Exhibit 54: GlaxoSmithKline – Organizational developments
Exhibit 55: GlaxoSmithKline – Geographic focus
Exhibit 56: GlaxoSmithKline – Segment focus
Exhibit 57: GlaxoSmithKline – Key offerings
Exhibit 58: GlaxoSmithKline – Key customers
Exhibit 59: Merck– Overview
Exhibit 60: Merck– Business segments
Exhibit 61: Merck– Organizational developments
Exhibit 62: Merck– Geographic focus
Exhibit 63: Merck– Segment focus
Exhibit 64: Merck– Key offerings
Exhibit 65: Merck– Key customers
Exhibit 66: Novartis – Overview
Exhibit 67: Novartis – Business segments
Exhibit 68: Novartis – Organizational developments
Exhibit 69: Novartis – Geographic focus
Exhibit 70: Novartis – Segment focus
Exhibit 71: Novartis – Key offerings
Exhibit 72: Novartis – Key customers
Exhibit 73: Pfizer: Overview
Exhibit 74: Pfizer – Business segments
Exhibit 75: Pfizer – Organizational developments
Exhibit 76: Pfizer – Geographic focus
Exhibit 77: Pfizer – Segment focus
Exhibit 78: Pfizer – Key offerings
Exhibit 79: Pfizer – Key customers



【掲載企業】

ALLERGAN, GlaxoSmithKline, Merck, Novartis, Pfizer

★調査レポート[非アルコール性脂肪肝疾患治療薬の世界市場2018-2022] (Global Non-alcoholic Fatty Liver Disease Therapeutics Market 2018-2022 / IRTNTR23695)販売に関する免責事項
[非アルコール性脂肪肝疾患治療薬の世界市場2018-2022] (Global Non-alcoholic Fatty Liver Disease Therapeutics Market 2018-2022 / IRTNTR23695)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆